Abstract library

152 results for "Biomarker".
#491 International Survey for the Use of Biomarkers and Molecular Imaging in Neuroendocrine Tumors (NET): What we are Using in Daily Practice
Introduction: Several guidelines have given recommendations for optimal use of biomarkers and molecular imaging. However, those guidelines’ implementation may not be always possible due to local policies or lack of access to several diagnostic studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: DR CHRISTOS Toumpanakis
#309 The Utility of Alpha Internexin as a Predictive Tissue Biomarker for Proliferation in Gastrointestinal and Pancreatic Neuroendocrine Tumors
Introduction: GEP-NETs are increasing but Ki-67 and CgA provide limited information regarding malignancy. A key unmet need is alternative biomarkers to assess the likelihood of local invasion or metastasis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
#1278 Midkine is a New Novel Serum Biomarker in Small Intestinal Neuroendocrine Tumors (SI-NETs).
Introduction: SI-NETs are often diagnosed late, which limits curative treatment options.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Kosmas Daskalakis
Keywords: Biomarker, SI-NET
#435 Olfactory Receptor 51E1 is a Novel Potential Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (SI-NETs) get late diagnosis. We discovered the olfactory receptor 51E1 (OR51E1) as a potential target to develop as a novel biomarker.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Tao Cui
Authors: Cui T, Ryberg U, Li S C, Cunningham J, ...
#1893 Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)
Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Aimee Hayes
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#582 Comparison of biomarkers in predicting presence and severity of carcinoid heart disease in patients with metastatic mid-gut neuroendocrine tumours
Introduction: Carcinoid heart disease (CHD) is evaluated using echocardiography. The utility of plasma biomarkers for detecting the presence/severity of CHD is under-explored.
Conference:
Category: Clinical
Presenting Author: Dr Rebecca Dobson
#994 Predictive Biomarkers of Response in Patients with Extrapulmonary Neuroendocrine Tumors (EPNET) Treated with Platin-based Chemotherapy
Introduction: EPNET, particularly advanced and Grade 3 (G3) tumors are often treated with chemotherapy. While many patients experience tumor response, those rarely live for more than two years. Predictive markers could potentially help us to tailor the best treatment for these patients (pts).
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: MD Juliana F Rego
#1434 CA19-9 As a Prognostic Biomarker in Pancreatic Neuroendocrine Tumors
Introduction: Carbohydrate antigen19-9 (CA19-9) is generally not considered as a biomarker in pancreatic neuroendocrine tumors (pNETs) since most pNETs present with normal range of CA19-9.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Kaizhou Jin
Authors: Luo G, Guo M, Liu Z, Liu C, ...
#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET
Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Jerome Cros
Authors: Bucau M, Cros J, Raffenne J, Rebours V, ...